Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis

Verdi, H; Koytak, ES; Onder, Fatih; Cinar, K; Idilman, R; Erden, E; Bozdayi, AM; Yurdaydin, M; Uzunalimoglu, D; Bozkaya, H

doi:10.2310/6650.2005.53706

Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis

Atıf İçin Kopyala

Verdi H., Koytak E., Onder O. , Cinar K., Idilman R., Erden E., ...Daha Fazla

JOURNAL OF INVESTIGATIVE MEDICINE, cilt.53, ss.353-359, 2005 (SCI İndekslerine Giren Dergi)

Cilt numarası: 53 Konu: 7
Basım Tarihi: 2005
Doi Numarası: 10.2310/6650.2005.53706
Dergi Adı: JOURNAL OF INVESTIGATIVE MEDICINE
Sayfa Sayıları: ss.353-359

Özet

Background: Peroxisome proliferator-activated receptor a (PPAR alpha) plays important roles in lipid metabolism. A recently discovered L162V polymorphism of the PPARa gene is associated with enhanced transcriptional activity. In this study, the frequency of L162V was investigated in nonalcoholic steatohepatitis (NASH) and genotype 1 hepatitis C virus (HCV)-related liver steatosis.